The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1

Diabetes. 2019 Dec;68(12):2223-2234. doi: 10.2337/db19-0049. Epub 2019 Oct 2.


Obesity is taking on worldwide epidemic proportions, yet effective pharmacological agents with long-term efficacy remain unavailable. Previously, we designed the iminosugar N-adamantine-methyloxypentyl-deoxynojirimycin (AMP-DNM), which potently improves glucose homeostasis by lowering excessive glycosphingolipids. Here we show that AMP-DNM promotes satiety and activates brown adipose tissue (BAT) in obese rodents. Moreover, we demonstrate that the mechanism mediating these favorable actions depends on oral, but not central, administration of AMP-DNM, which ultimately stimulates systemic glucagon-like peptide 1 (GLP1) secretion. We evidence an essential role of brain GLP1 receptors (GLP1r), as AMP-DNM fails to promote satiety and activate BAT in mice lacking the brain GLP1r as well as in mice treated intracerebroventricularly with GLP1r antagonist exendin-9. In conclusion, AMP-DNM markedly ameliorates metabolic abnormalities in obese rodents by restoring satiety and activating BAT through central GLP1r, while improving glucose homeostasis by mechanisms independent of central GLP1r.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Deoxynojirimycin / analogs & derivatives*
  • 1-Deoxynojirimycin / pharmacology
  • Adamantane / analogs & derivatives*
  • Adamantane / pharmacology
  • Adipose Tissue, Brown / drug effects*
  • Animals
  • Brain / drug effects
  • Brain / physiology
  • Glucagon-Like Peptide 1 / physiology*
  • Glucose / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Obesity / drug therapy
  • Obesity / metabolism
  • Rats
  • Rats, Wistar
  • Satiation / drug effects*
  • Signal Transduction / drug effects


  • N-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin
  • 1-Deoxynojirimycin
  • Glucagon-Like Peptide 1
  • Glucose
  • Adamantane